α-
Synuclein is the major
protein associated with
Lewy body dementia,
Parkinson's disease and
multiple system atrophy. Since α-
synuclein is present in the brain in physiological conditions as a presynaptic
protein, it is crucial to characterize disease-associated modifications to develop an in vivo
biomarker. With the aim to develop
antibodies showing high specificity and sensitivity for disease-associated α-
synuclein, synthetic
peptides containing different amino acid sequences were used for immunization of mice. After generation of α-
synuclein aggregates, ELISA and immunoblotting were used to test the specificity of
antibodies. Tissue microarray sections originating from different human α-
synucleinopathies were used to compare immunostaining with other, commercially available
antibodies. Immunization of mice with the
peptide TKEGVVHGVATVAE (
amino acid 44-57 of α-
synuclein) resulted in the generation of a
monoclonal antibody (5G4), which was able to bind aggregated α-
synuclein preparation in sandwich ELISA or coated on magnetic beads. 5G4 proved to be superior to other
antibodies in comparative immunohistochemical studies by revealing more widespread and distinct α-
synuclein pathology. Immunoblotting of human brain tissue revealed an additional band seen in
dementia with Lewy bodies, whereas the band representing monomeric α-
synuclein was very weak or lacking. In summary, the 5G4 antibody is most promising for re-evaluation of archival material and may offer new perspective for the development of in vivo diagnostic assays for detecting disease-associated α-
synuclein in body fluids.